ANSM Publishes Safety Information on Sener Diagnostics Autoplak Advance Automated Bacteriology Device

On 7 July 2026, the French National Agency for the Safety of Medicines and Health Products (ANSM) published a user safety information notice concerning the Sener Diagnostics Autoplak Advance automated bacteriology device. The notice is addressed to medical testing laboratories and highlights post-market safety actions, user notification and quality system closed-loop management for IVD devices.

Core Content

Safety Information: Bacteriology Automated Device Autoplak Advance, Manufacturer Sener Diagnostics

The French National Agency for the Safety of Medicines and Health Products (ANSM) published a user safety information notice on 7 July 2026. The notice relates to an in vitro diagnostic medical device safety matter concerning the Autoplak Advance automated device.

According to the ANSM public page, this safety information is registered under number R2619050 and is addressed to medical testing laboratories. ANSM states that it has been informed that Sener Diagnostics is implementing a safety action. Affected users have already received the notification letter provided by the company.

ANSM has recorded the safety action under registration number R2619050. The regulatory page advises that users with questions about the safety action should contact the originator of the action directly, namely Sener Diagnostics.

The ANSM page also makes available the formal notification letter issued by Sener Diagnostics on 7 July 2026 for review by relevant users. For automated devices used in medical testing laboratories, user notification, batch or configuration identification, field correction and ongoing communication are typically important components of post-market surveillance.

This translation is based on the main information available on the ANSM public page. Site navigation, menu items, footer links and other non-content information have been removed. The original link is retained in the source note below.

Source and Applicability

• Source authority: ANSM Medical Devices
• Original date: 7 July 2026
• Article publication date: 9 July 2026
• Source: ANSM Medical Devices
• Original link: https://ansm.sante.fr/informations-de-securite/bacteriologie-automate-autoplak-advance-sener-diagnostics

This article is compiled from publicly available safety information published by ANSM. Specific requirements are subject to the latest official publications of the regulatory authority.

Regulatory Interpretation and Business Impact

What This Means for Medical Device Manufacturers

For updates of this type published by ANSM Medical Devices, companies should first determine whether the information concerns regulatory policy, guidelines and standards, recall and safety, product performance, quality systems or post-market surveillance. Different categories of information have different implications for registration pathways, technical documentation, labelling and instructions for use, risk management and market maintenance, and should not be treated simply as general industry news.

For medical device manufacturers, the key is to convert the news into executable compliance actions: confirm whether similar products, similar technical routes or similar risk points are involved; check whether existing documentation still supports the requirements of the target market; and update risk management, performance verification, clinical evaluation, labelling and instructions for use, distributor communication and post-market surveillance records where necessary.

Documents to Review on a Priority Basis

• Intended use and classification basis
• ISO 13485 quality system certification
• Risk management file
• Performance verification data
• Clinical evaluation or clinical evidence
• Labelling and instructions for use
• Authorisation documents and existing registration certificates

Common Risks

• Unclear classification determination
• Incomplete evidence chain in documentation
• Labelling and instructions for use not localised
• Unclear responsibilities of the authorised representative
• Insufficient post-market maintenance arrangements

Quality System and Post-Market Considerations

The value of official information such as this ANSM notice for medical device manufacturers lies not in knowing about a single event, but in reminding companies to convert publicly available regulatory information into internal compliance actions. Companies should first determine whether the information concerns their own products, similar test items, similar device platforms, the same technical route or the same use scenarios, and should record the original link, publication date, scope of application and internal assessment conclusions in a regulatory intelligence log.

From a registration documentation perspective, the Autoplak Advance automated device safety action may affect product risk management, performance verification, clinical evaluation, labelling and instructions for use, quality system records and post-market surveillance documents. If a company already markets similar products in the European Union, Australia, ASEAN, the Middle East or other GHWP member states, it should further confirm whether the performance claims, applicable specimens, user types, limitations, warnings and user notification mechanisms in the technical documentation are supported by sufficient evidence.

From a quality system perspective, companies need to check whether complaint handling, CAPA, batch traceability, distributor notification and field safety corrective action processes can genuinely operate. Many companies focus on document submission during the registration stage but neglect post-market information collection and trend analysis. Once a regulatory authority publishes similar safety information, a company without internal assessment records, risk evaluation conclusions and handling pathways will be at a significant disadvantage in customer audits, distributor communications or regulatory inquiries.

International Registration Strategy

From an international registration strategy perspective, the system configuration, laboratory workflow, user training and field correction of automated bacteriology devices should not be handled in a single country only. For companies that already use CE, ISO 13485, MDSAP, NMPA or other market documentation for reuse, they should assess whether the event affects the credibility of the same documentation set in other target markets. For IVD products, software products, automated testing devices and high-risk consumables in particular, review bodies usually focus on whether performance evidence is reproducible, whether risk control is closed-loop, and whether labelling and instructions for use truthfully reflect limitations.

Companies are advised to establish a fixed regulatory intelligence handling process: first, confirm the official source and original date; second, determine whether existing registrations, projects under development or exported products are affected; third, have regulatory, quality, R&D, clinical and marketing teams jointly assess whether documentation updates or internal CAPA initiation are required; and fourth, incorporate the assessment results into the next registration, change, renewal and customer audit materials. This is how news information can be transformed into genuine international registration competitiveness.

In practical implementation, companies should also break the information down into a checkable task list: the regulatory team confirms whether similar regulatory actions already exist in target countries; the quality team confirms whether related complaints or adverse events exist; the R&D team confirms whether performance verification and design inputs remain adequate; the clinical or medical team confirms whether there are risks in result interpretation and intended use scenarios; and the marketing and distributor teams confirm whether customer communication materials are accurate and consistent. For projects currently being submitted or about to be submitted, these assessments should be documented in writing as supporting materials for subsequent deficiency responses, changes, renewals or customer audits.

If a company uses the same product platform to enter multiple GHWP member states, particular attention should be paid to the boundaries of documentation reuse. The same risk management report, performance verification report or labelling and instructions for use may require different supplementary explanations under different regulatory systems. Companies should not wait for regulatory authorities to raise questions before supplementing documentation; instead, they should proactively complete a small-scale gap assessment after seeing official safety information. This can both reduce post-market compliance risks and improve the stability of subsequent international registration projects.

FAQ

Can the ANSM safety information on the Sener Diagnostics Autoplak Advance automated device, published on 7 July 2026, be used directly as a basis for regulatory submission?

No. This article is intended for preliminary understanding and project assessment. Formal submissions must still be based on the latest requirements of the target country's regulatory authority, the product classification conclusion and the company's actual documentation.

What should companies do first after seeing such an update?

Companies should first conduct a documentation gap assessment to determine whether the update affects the registration pathway, technical documentation, labelling, quality system or post-market maintenance.

Content Review and Scope of Application

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI International Medical Device Registration Project Team

Source principles: Priority is given to official regulatory authorities, international organisations, standards bodies and publicly available regulatory materials; industry media and project experience are used only as supporting references.

Scope of application: This article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of target country regulatory authorities, testing conclusions or legal opinions.

To assess a registration pathway, please provide the product name, intended use, target countries and existing documentation basis. AIMEILI can assist in determining the registration pathway, documentation gaps and compliance risks.